RayzeBio Revenue and Competitors

Claim your profile

Location

#978

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • RayzeBio's estimated annual revenue is currently $9.6M per year.(i)
  • RayzeBio's estimated revenue per employee is $133,472
  • RayzeBio's total funding is $258M.

Employee Data

  • RayzeBio has 72 Employees.(i)
  • RayzeBio grew their employee count by 118% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$27.4M146-5%$160MN/A
#2
$3.7M24N/AN/AN/A
#3
$18.1M93-3%$24.1MN/A
#4
$47.1M304-3%N/AN/A
#5
$48.1M28014%$403MN/A
#6
$459.2M206854%$242.6MN/A
#7
$0.9M14133%$6.1MN/A
#8
$14.9M79-12%$140MN/A
#9
$29M187-1%N/AN/A
#10
$3.7M24N/AN/AN/A

Leader in targeted radiopharmaceuticals to improving cancer patient survival. Broad pipeline of innovative drugs against solid tumor targets

keywords:N/A

$258M

Total Funding

72

Number of Employees

$9.6M

Revenue (est)

118%

Employee Growth %

N/A

Valuation

N/A

Accelerator

RayzeBio News

2021-06-16 - RayzeBio Snags $108M for Cancer Drug Efforts

San Diego-based RayzeBio, a pharmaceuticals company which says it is developing targeted radiopharmaceutical drugs for cancer, has raised $108M in its Series C funding. The company said it has now raised a total of $258M. The new funding was led by Venrock Healthcare Capital Partners and also in ...

2021-06-15 - RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

RayzeBio, Inc., which is discovering and developing a broad pipeline of innovative targeted radiopharmaceutical drugs for cancer, today announced a $108 million Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$20.8M7220%N/A
#2
$11.2M72-5%N/A
#3
$13.6M72-41%N/A
#4
$13.6M72-13%N/A
#5
$9.4M72N/AN/A